Leukemia Research
Volume 33, Issue 11 , Pages 1469-1474 , November 2009

Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts

Received 15 October 2008 ,Revised 24 May 2009 ,Accepted 26 June 2009.

References 

  1. Bowen DT, Hellström-Lindberg E. Best supportive care for the anaemia of myelodysplasia: inclusion of recombinant erythropoietin therapy?. Leuk Res. 2001;25:19–21
  2. Malcovati L, Della Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for decision making. J Clin Oncol. 2005;23:7594–7603
  3. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndrome. J Clin Oncol. 2007;25:3503–3510
  4. Konen E, Ghoti H, Goitein O, Goitein O, Winder A, Kushnir T, et al. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2* technique. Am J Hematol. 2007;82:1013–1016
  5. Chacko J, Pennell DJ, Tanner MA, Hamblin TJ, Wonke B, Levy T, et al. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol. 2007;138:587–593
  6. Di Tucci A, Matta G, Deplano S, Gabbas A, Depau C, Derudas D, et al. Myocardial iron overload assessment by t2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica. 2008;93:1385–1388
  7. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vradiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835–3839
  8. Greenberg P, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088
  9. Sanz G, Nomdeden B, Such E, Bernal T, Belkaid M, Ardanaz MT, et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome (abstr.). Blood. 2008;112:238
  10. Čermák J, Michalová K, Březinová J, Zemanová Z. A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q-syndrome from refractory anemia in primary myelodysplastic syndrome. Leuk Res. 2003;27:221–229
  11. Kantarjian H, Brien O, Ravandi S, Cortes F, Shan J, Bennett JM, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts that accounts for events not considered in the original international prognostic scoring system. Cancer. 2008;113:1351–1361
  12. Porter JB. Practical management of iron overload. Br J Haematol. 2001;115:239–252
  13. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce N, et al. Cardiovascular T2 star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171–2179
  14. St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105:855–861
  15. Telfer PT, Prescott E, Holden S, Walker M, Hoffbrand AV, Wonke B. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalasemia major. Br J Haematol. 2000;110:971–977
  16. Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood. 2003;101:4632–4639
  17. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331:574–578
  18. Taher A, Nathan D, Porter J. Evaluation of iron levels to avoid the clinical sequelae of iron overload. Semin Hematol. 2007;44:S2–S6
  19. Schafer AI, Cheron RG, Dluhy R, Cooper B, Gleason RE, Soeldner JS, et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med. 1981;304:319–324
  20. Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008;22:538–543
  21. Oliva EN, Dimitrov BD, Benedetto F, D Angelo AD, Nobile F. Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome. Leuk Res. 2005;29:1217–1219
  22. Goldberg SL. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes. Leuk Res. 2007;31(Suppl. 3):S16–S22
  23. Buja LM, Roberts WC. Iron in the heart. Am J Med. 1971;51:209–221
  24. Porter JB, Tanner MA, Pennell DJ, Eleftheriou P . Improved myocardial T2* in transfusion dependent anemias receiving ICL670 (deferiprone) (abstr.). Blood. 2005;106;abstr.3600
  25. Leitch HA. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res. 2007;31(Suppl. 3):S7–S9
  26. Rose C, Brechignac S, Vassilief D, Beyne-Rauzy O, Stamatoullas A, Larbaa D, et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM (abstr.). Blood. 2007;110;abstr. 249
  27. Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol. 2008;83:858–861

PII: S0145-2126(09)00341-5

doi: 10.1016/j.leukres.2009.06.033

Leukemia Research
Volume 33, Issue 11 , Pages 1469-1474 , November 2009

Article Tools

* Image Usage & Resolution